IGF-1 LR3
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A long-acting analog of IGF-1 marketed for muscle growth, fat loss, and recovery. Extended activity is documented, but growth and repair claims rest mainly on animal and mechanism studies; human evidence is minimal and safety data are largely absent. Hypoglycemia is common and sometimes fatal with insulin, and its growth-signaling effects raise a real, unresolved cancer concern. Not an approved drug in the US; supply consists of unregulated products sold online.
Read Full recordStudied uses & evidence
Studied uses(6)
Enhanced muscle protein synthesis and hyperplasia
LowStimulates muscle cell proliferation in culture, but animal growth studies show no consistent benefit.
Extended biological activity vs native IGF-1
MediumAnimal studies confirm reduced IGFBP binding and altered circulation, but no human pharmacokinetic data exists.
Improved nutrient partitioning and glucose uptake
LowLowered glucose and insulin in calves, though the partitioning effect appears weaker than commonly claimed.
Evidence limits
- Evidence Level
- Preclinical
No human clinical trials have been conducted on IGF-1 LR3 specifically. All evidence comes from animal models (guinea pigs, sheep, mice) and in vitro cell culture studies. Human safety and efficacy data are extrapolated from native IGF-1 clinical studies (mecasermin/Increlex). The compound remains a research reagent without regulatory pathway for human therapeutic use.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
AbsoluteExtended-half-life IGF-1 directly promotes tumor cell proliferation and inhibits apoptosis.
Diabetic retinopathy
HighProlonged IGF-1 receptor activation worsens retinal neovascularization.
Hypoglycemia-prone individuals
HighIGF-1 LR3 can cause severe hypoglycemia. The duration of glucose lowering in humans is unestablished.
Organ enlargement risk (high-dose/prolonged use)
ModerateChronic supraphysiological IGF-1 can cause visceral organ enlargement (heart, kidneys, intestines).
Risk summary(10)
Risks = level of concern: High · Moderate · Low · Theoretical
Hypoglycemia (low blood sugar) - most common acute side effect, reported at virtually all dose levels; risk dramatically increased when combined with insulin, with fatalities reported
HighPotential cancer acceleration - promotes cell growth and inhibits apoptosis; one observational study linked higher endogenous IGF-1 to increased all-cancer mortality in older men; it did not measure LR3 risk
ModerateInsulin resistance with chronic use - frequent use can push the body toward insulin resistance, creating long-term metabolic complications
TheoreticalFluid retention and edema - water retention is a commonly reported side effect
LowJoint pain and stiffness - musculoskeletal discomfort is frequently reported
ModerateAcromegaly-like changes with prolonged use - potential for bone and soft tissue overgrowth with long-term exposure
LowEndocrine disruption - suppression of natural growth hormone and IGF-1 production via negative feedback
ModerateNo human clinical trial safety data - all safety information is extrapolated from animal studies and native IGF-1 human data
HighUnregulated product quality - unregulated products sold online are not made to pharmaceutical manufacturing standards (GMP); contamination and dosing inaccuracies are possible
HighHeadaches and nausea - commonly reported at various dose levels
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.